Evolving role of aldosterone blockers alone and in combination with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in hypertension management: A review of mechanistic and clinical data

American Heart Journal

Volumn 147, Issue 4, 2004, Pages 564-572

  Black, Henry R ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CHLORTALIDONE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPLERENONE; HYDROCHLOROTHIAZIDE; LOOP DIURETIC AGENT; MINERALOCORTICOID ANTAGONIST; SPIRONOLACTONE; VERAPAMIL;

ALDOSTERONE BLOOD LEVEL; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; CREATININE CLEARANCE; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG APPROVAL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG WITHDRAWAL; ESSENTIAL HYPERTENSION; GYNECOMASTIA; HEART INJURY; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; HYPERKALEMIA; HYPERTENSION; IMPOTENCE; LIBIDO DISORDER; LONG TERM CARE; MASTALGIA; MENSTRUAL IRREGULARITY; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK ASSESSMENT; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

EID: 3142615814     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ahj.2003.10.034     Document Type: Article

References (80)

1. Heart and stroke facts: 2002 statistical supplement. Dallas, Tex: American Heart Association; 2001
2. The Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 157:1997;2413-2446
3. Guidelines Subcommittee. 1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension. Blood Press. 8:(Suppl 1):1999;9-43
4. Lenfant C. Reflections on hypertension control rates A message from the director of the National Heart, Lung, and Blood Institute. Arch Intern Med. 162:2002;131-132
5. Vasan R.S., Beiser A., Seshadri S., et al. Residual lifetime risk for developing hypertension in middle-aged women and men The Framingham Heart Study. JAMA. 287:2002;1003-1010
6. Moser M., Black H.R. The role of combination therapy in the treatment of hypertension. Am J Hypertens. 11:1998;73-78S
7. Jackson E.K. Renin and angiotensin. Hardman J.G., Limbird L.E. Goodman and Gilman's the pharmacological basis of therapeutics. 10th ed:2001;809-841 McGraw-Hill, New York
8. Young M.J., Funder J.W. Mineralocorticoid receptors and pathophysiological roles for aldosterone in the cardiovascular system. J Hypertens. 20:2002;1465-1468
9. Stier C.T., Chander P.N., Rocha R. Aldosterone as a mediator in cardiovascular injury. Cardiol Rev. 10:2002;97-107
10. Weber K.T. Mechanisms of disease Aldosterone in congestive heart failure. N Engl J Med. 345:2001;1689-1697
11. Stowasser M. New perspectives on the role of aldosterone excess in cardiovascular disease. Clin Exp Pharmacol Physiol. 28:2001;783-791
12. Rocha R., Williams G.H. Rationale for the use of aldosterone antagonists in congestive heart failure. Drugs. 62:2002;723-731
13. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 341:1999;709-717
14. Plouin P.F., Corvol P., Menard J. Influence of beta-blockade on aldosterone metabolism under normal and low sodium diet in man. Biomedicine. 27:1977;233-235
15. Sato A., Saruta T. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J Int Med Res. 29:2001;13-21
16. Borghi C., Boschi S., Ambrosioni E., et al. Evidence of a partial escape of renin-angiotensin-aldosterone blockade in patients with acute myocardial infarction treated with ACE inhibitors. J Clin Pharmacol. 33:1993;40-45
17. McKelvie R., Usuf S., Pericak D., et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure Randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study: The RESOLVD Pilot Study Investigators. Circulation. 100:1999;1056-1064
18. Naruse M., Tanabe A., Sato A., et al. Aldosterone breakthrough during angiotensin II receptor antagonist therapy in stroke-prone spontaneously hypertensive rats. Hypertension. 40:2002;28-33
19. Pitt B. "Escape" of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor Implications for therapy. Cardiovasc Drugs Ther. 9:1995;145-149
20. Sato A., Suzuki Y., Shibata H., et al. Plasma aldosterone concentrations are not related to the degree of angiotensin-converting enzyme inhibition in essential hypertensive patients. Hypertens Res. 23:2000;25-31
21. Struthers A.D. Aldosterone escape during angiotensin-converting enzyme inhibition therapy in chronic heart failure. J Card Fail. 2:1996;47-54
22. Mizuno Y., Yoshimura M., Yasue H., et al. Aldosterone production is activated in failing ventricle in humans. Circulation. 103:2001;72-77
23. Hatakeyama H., Miyamori I., Fujita T., et al. Vascular aldosterone Biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells. J Biol Chem. 269:1994;24316-24320
24. MacKenzie S.M., Clark C.J., Fraser R., et al. Expression of 11β-hydroxylase and aldosterone synthase genes in the rat brain. J Mol Endocrinol. 24:2000;321-328
25. Bonvalet J.P., Alfaidy N., Farman N., et al. Aldosterone Intracellular receptors in human heart. Eur Heart J. 16:(Suppl N):1995;92-97
26. Kornel L. Colocalization of 11 beta-hydroxysteroid dehydrogenase and mineralocorticoid receptors in cultured vascular smooth muscle cells. Am J Hypertens. 7:1994;100-103
27. Coirini H., Magarinos A.M., De Nicola A.F., et al. Further studies of brain aldosterone binding sites employing new mineralocorticoid and glucocorticoid receptor markers in vitro. Brain Res. 361:1985;212-216
28. Wehling M., Neylon C.B., Fullerton M., et al. Nongenomic effects of aldosterone on intracellular calcium in vascular smooth muscle cells. Circ Res. 76:1995;973-979
29. Alzamora R., Michea L., Marusic E.T. The role of 11-β-hydroxysteroid dehydrogenase in nongenomic aldosterone effects in human arteries. Hypertension. 35:2000;1099-1104
30. Conn J.W., Knopf R.F., Nesbit R.M. Clinical characteristics of primary aldosteronism from an analysis of 145 cases. Am J Surg. 107:1964;159-172
31. Halimi J.-M., Mimram A. Albuminuria in untreated patients with primary aldosteronism or essential hypertension. J Hypertens. 13:1995;1801-1802
32. Nishimura M., Uzu T., Fuji T., et al. Cardiovascular complications in patients with primary aldosteronism. Am J Kidney Dis. 33:1999;261-266
33. Rossi G.P., Sachetto A., Visentin P., et al. Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension. 27:1996;1039-1045
34. Blacher J., Amah G., Girerd X., et al. Association between increased plasma levels of aldosterone and decreased systemic arterial compliance in subjects with essential hypertension. Am J Hypertens. 10:1997;1326-1334
35. Fagard R.H., Lijnen P.J., Petrov V.V. Opposite associations of circulating aldosterone and atrial natriuretic peptide with left ventricular diastolic function in essential hypertension. J Hum Hypertens. 12:1998;195-202
36. Schlaich M.P., Schobel H.P., Hilgers K., et al. Impact of aldosterone on left ventricular structure and function in young normotensive and mildly hypertensive subjects. Am J Cardiol. 85:2000;1199-1206
37. Schunkert H., Hense H.W., Muscholl M., et al. Associations between circulating components of the renin-angiotensin-aldosterone system and left ventricular mass. Heart. 77:1997;24-31
38. Gomez-Sanchez C.E., Gomez-Sanchez E.P. Role of central mineralocorticoid receptors in cardiovascular disease. Curr Hypertens Rep. 3:2001;263-269
39. Purdy R.E., Weber M.A., Drayer J.I. Vasoconstrictor effects of aldosterone in isolated vascular tissue. Clin Exp Hypertens. 4:1982;1583-1591
40. Reid J.L., Zivin J.A., Kopin I.J. Central and peripheral adrenergic mechanisms in the development of deoxycorticosterone-saline hypertension in rats. Circ Res. 37:1975;569-579
41. Wang W. Chronic administration of aldosterone depresses baroreceptor reflex function in the dog. Hypertension. 24:1994;571-575
42. Weber K.T., Brilla C.G. Pathological hypertrophy and cardiac interstitium Fibrosis and renin-angiotensin-aldosterone system. Circulation. 83:1991;1849-1865
43. Young M., Fullerton M., Dilley R., et al. Mineralocorticoids, hypertension and cardiac fibrosis. J Clin Invest. 93:1994;2578-2583
44. Young M., Head G., Funder J. Determinants of cardiac fibrosis in experimental hypermineralocorticoid states. Am J Physiol. 269:1995;E657-662
45. Benetos A., Lacolley P., Safar M.E. Prevention of aortic fibrosis by spironolactone in spontaneously hypertensive rats. Arterioscler Thromb Vasc Biol. 17:1997;1152-1156
46. Farquharson C.A., Struthers A.D. Aldosterone induces acute endothelial dysfunction in vivo in humans Evidence of an aldosterone-induced vasculopathy. Clin Sci (Colch). 103:2002;425-431
47. Rocha R., Stier C.T. Jr, Kifor I., et al. Aldosterone A mediator of myocardial necrosis and renal arteriopathy. Endocrinology. 141:2000;3871-3878
48. Hatakeyama H., Miyamori I., Fulita T., et al. Vascular aldosterone Biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells. J Biol Chem. 269:1994;316-320
49. Silvestre J.-S., Robert V., Heymes C., et al. Myocardial production of aldosterone and corticosterone in the rat. J Biol Chem. 273:1998;4883-4891
50. Gomez-Sanchez C.E., Zhou M.Y., Cozza E.N., et al. Aldosterone biosynthesis in the rat brain. Endocrinology. 138:1997;3369-3373
51. MacKenzie S.M., Clark C.J., Ingram M.C., et al. Corticosteroid production by fetal rat hippocampal neurons. Endocr Res. 26:2000;531-535
52. Gomez-Sanchez E.P. Mineralocorticoid modulation of central control of blood pressure. Steroids. 60:1995;69-72
53. Sun Y., Ramires F.J.A., Weber K.T. Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion. Cardiovasc Res. 35:1997;138-147
54. Brilla C.G. Aldosterone and myocardial fibrosis in heart failure. Herz. 25:2000;299-306
55. Brilla C.G., Weber K.T. Reactive and reparative myocardial fibrosis in arterial hypertension in the rat. Cardiovasc Res. 26:1992;671-677
56. Ramires F.J.A., Sun Y., Weber K.T. Myocardial fibrosis associated with aldosterone or angiotensin administration. J Mol Cell Cardiol. 30:1998;475-483
57. Van Belle E., Bauters C., Wernert N., et al. Neointimal thickening after balloon denudation is enhanced by aldosterone and inhibited by spironolactone, an aldosterone antagonist. Cardiovasc Res. 29:1995;27-32
58. Rocha R., Chander P.N., Khanna K., et al. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension. 31:1998;451-458
59. Rocha R., Chander P.N., Zuckerman A., et al. Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension. 33:1999;232-237
60. de Gasparo M., Joss U., Ramjoue H.P., et al. Three new epoxy-spironolactone derivatives Characterization in vivo and in vitro. J Pharmacol Exp Ther. 240:1987;650-656
61. Delyani J.A., Robinson E.L., Rudolph A.E. Effect of a selective aldosterone receptor antagonist in myocardial infarction. Am J Physiol Heart Circ Physiol. 281:2001;H647-654
62. Martinez D.V., Rocha R., Matsumura M., et al. Cardiac damage prevention by eplerenone Comparison with low sodium diet or potassium loading. Hypertension. 39:(2 part 2):2002;614-618
63. Rajagopalan S., Duquaine D., King S., et al. Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation. 105:2002;2212-2216
64. Ward M.R., Kanellakis P., Ramsey D., et al. Eplerenone suppresses constrictive remodeling and collagen accumulation after angioplasty in porcine coronary arteries. Circulation. 104:2001;467-472
65. Mantero F., Lucarelli G. Aldosterone antagonists in hypertension and heart failure. Ann Endocrinol (Paris). 61:2000;52-60
66. Weinberger M.H., Roniker B., Krause S.L., et al. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens. 15:2002;709-716
67. Flack J.M., Oparil S., Pratt J.H., et al. Efficacy and tolerability of eplerenone and losartan in hypertensive black patients and white patients. J Am Coll Cardiol. 41:2003;1148-1155
68. Sato A., Suzuki Y., Saruta T. Effects of spironolactone and angiotensin-converting enzyme inhibitor on left ventricular hypertrophy in patients with essential hypertension. Hypertens Res. 22:1999;17-22
69. Farquharson C.A., Struthers A.D. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation. 101:2000;594-597
70. Barr C.S., Lang C.C., Hanson J., et al. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol. 76:1995;1259-1265
71. Krum H., Nolly H., Workman D., et al. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension. 40:2002;117-123
72. Burgess E., Yves Lacourcière Y., Luis M., et al. Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension. Clin Ther. 25:2003;2388-2404
73. Epstein M., Buckalew V., Martinez F., et al. Antiproteinuric efficacy of eplerenone, enalapril, and eplerenone/enalapril combination in diabetic hypertensives with microalbuminuria. Am J Hypertens. 15:(4 Suppl 1):2002;A24
74. Pitt B, Reichek N, Willenbrock R, et al. The effects of eplerenone, enalapril and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-LVH study. Circulation 2003 (in press)
75. Pitt B., Remme W., Zannad F., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 348:2003;1309-1321
76. Myers M.G. Methods for evaluating the duration of action of once-daily antihypertensive therapy. Blood Press Monit. 8:2003;161-163
77. White W.B., Carr A.A., Krause S., et al. Assessment of the novel selective aldosterone blocker, eplerenone, using ambulatory and clinical blood pressure in patients with systemic hypertension. Am J Cardiol. 92:2003;38-42
78. White W.B., Duprez D., St Hillaire R., et al. Effects of the highly selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in older patients with systolic hypertension. Hypertension. 41:2003;1021-1026
79. Burgess E, Ruilope LM, Francischetti E, et al. Efficacy and safety of adding a second antihypertensive agent to eplerenone in patients with essential hypertension [abstract]. Eighteenth Annual Scientific Meeting and Exposition of the American Society of Hypertension, May 14-17, 2003, New York, NY
80. Willenbrock R, van Mieghem W, von Behren V, et al. Addition of eplerenone to calcium channel blockers and beta blockers improves blood pressure control [abstract]. Eighteenth Annual Scientific Meeting and Exposition of the American Society of Hypertension, May 14-17, 2003, New York, NY